Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.7759/cureus.11779 http://scihub22266oqcxt.onion/10.7759/cureus.11779 33409026!7779177!33409026     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cureus 2020 ; 12 (11): e11779 Nephropedia Template TP {{tp|p=33409026|t=2020. The Role of Vitamin C as Adjuvant Therapy in COVID-19 |pdf=|usr=}}{{33409026}} gab.com Text The Role of Vitamin C as Adjuvant Therapy in COVID-19 JO: Cureus http://www.kidney.de/pget.php?&tw=1&pmid=33409026 #FOAvip Background and objective The anti-inflammatory properties of vitamin C (VC) and the promising results it has shown in the treatment for common cold have prompted clinicians to use it as adjuvant therapy in the treatment of COVID-19. The purpose of this study was to find out the role of VC as adjunctive therapy in coronavirus disease 2019 (COVID-19). Methodology This study was conducted from March to July 2020 in the COVID-19 unit of a tertiary care hospital in Karachi. In this randomized controlled trial (RCT), one group received the intervention [50 mg/kg/day of intravenous (IV) VC] along with the standard therapy, and the other group received standard therapy only. Data such as age, gender, vitals, and biochemical values as well as outcomes including the number of days required for treatment, hospital stay, need for ventilation, and mortality were compared between the two groups and recorded using a self-structured questionnaire. Results COVID-19 patients who received IV VC became symptom-free earlier (7.1 +/- 1.8 vs. 9.6 +/- 2.1 days, p-value: <0.0001) and spent fewer days in the hospital (8.1 +/- 1.8 vs. 10.7 +/- 2.2 days, p-value: <0.0001) compared to those who received standard therapy only. However, there was no significant difference in the need for mechanical ventilation (p-value: 0.406) and mortality (p-value: 0.31) between the two groups. Conclusion VC can significantly improve clinical symptoms in patients affected with COVID-19; however, it had no impact on mortality and the need for mechanical ventilation. More large-scale studies are required to further assess the role of VC in the treatment of COVID-19. Twit Text FOAVip The Role of Vitamin C as Adjuvant Therapy in COVID-19 ????Cureus http://www.kidney.de/pget.php?&tw=1&pmid=33409026 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33409026 #FOAvip English Wikipedia <ref>{{Cite pmid|33409026}}</ref> The Role of Vitamin C as Adjuvant Therapy in COVID-19 #MMPMID33409026 Kumari P; Dembra S; Dembra P; Bhawna F; Gul A; Ali B; Sohail H; Kumar B; Memon MK; Rizwan A Cureus 2020[Nov]; 12 (11): e11779 PMID33409026show ga Background and objective The anti-inflammatory properties of vitamin C (VC) and the promising results it has shown in the treatment for common cold have prompted clinicians to use it as adjuvant therapy in the treatment of COVID-19. The purpose of this study was to find out the role of VC as adjunctive therapy in coronavirus disease 2019 (COVID-19). Methodology This study was conducted from March to July 2020 in the COVID-19 unit of a tertiary care hospital in Karachi. In this randomized controlled trial (RCT), one group received the intervention [50 mg/kg/day of intravenous (IV) VC] along with the standard therapy, and the other group received standard therapy only. Data such as age, gender, vitals, and biochemical values as well as outcomes including the number of days required for treatment, hospital stay, need for ventilation, and mortality were compared between the two groups and recorded using a self-structured questionnaire. Results COVID-19 patients who received IV VC became symptom-free earlier (7.1 +/- 1.8 vs. 9.6 +/- 2.1 days, p-value: <0.0001) and spent fewer days in the hospital (8.1 +/- 1.8 vs. 10.7 +/- 2.2 days, p-value: <0.0001) compared to those who received standard therapy only. However, there was no significant difference in the need for mechanical ventilation (p-value: 0.406) and mortality (p-value: 0.31) between the two groups. Conclusion VC can significantly improve clinical symptoms in patients affected with COVID-19; however, it had no impact on mortality and the need for mechanical ventilation. More large-scale studies are required to further assess the role of VC in the treatment of COVID-19. äThe Role of Vitamin C as Adjuvant Therapy in COVID-19 (epmc).pdf DeepDyve Pubget Overpricing